bioAffinity Technologies wins Japan patent allowance for CyPath Lung AI algorithm

PUBT · 1d ago
bioAffinity Technologies wins Japan patent allowance for CyPath Lung AI algorithm
  • bioAffinity Technologies received a notice of allowance from Japan’s patent office for an AI-driven method supporting its CyPath Lung cancer-risk prediction test.
  • The filing covers early-stage lung cancer detection in sputum using automated flow cytometry with machine learning.
  • The company expects the Japanese patent to be issued following payment of the required fee.
  • The portfolio includes 22 granted patents worldwide, with 36 applications pending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261008743266) on October 08, 2026, and is solely responsible for the information contained therein.